These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 7692295

  • 1. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B.
    N Engl J Med; 1993 Oct 21; 329(17):1219-24. PubMed ID: 7692295
    [Abstract] [Full Text] [Related]

  • 2. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 21; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 3. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
    Lindén O, Tennvall J, Cavallin-Ståhl E, Darte L, Garkavij M, Lindner KJ, Ljungberg M, Ohlsson T, Sjögreen K, Wingårdh K, Strand SE.
    Clin Cancer Res; 1999 Oct 21; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
    [Abstract] [Full Text] [Related]

  • 4. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
    Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM.
    N Engl J Med; 1993 Aug 12; 329(7):459-65. PubMed ID: 7687326
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 12; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

  • 6. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
    Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA.
    J Clin Oncol; 1989 Aug 12; 7(8):1027-38. PubMed ID: 2666588
    [Abstract] [Full Text] [Related]

  • 7. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma.
    Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP.
    J Clin Oncol; 1992 Nov 12; 10(11):1696-711. PubMed ID: 1403053
    [Abstract] [Full Text] [Related]

  • 8. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.
    Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL.
    J Clin Oncol; 1996 Jul 12; 14(7):1974-81. PubMed ID: 8683227
    [Abstract] [Full Text] [Related]

  • 9. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
    Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, Grillo-López A, Chinn P, Varns C, Ning SC, Fowler S, Deb N, Becker M, Marquez C, Levy R.
    Clin Cancer Res; 1996 Mar 12; 2(3):457-70. PubMed ID: 9816191
    [Abstract] [Full Text] [Related]

  • 10. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 12; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 11. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug 12; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 12; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 13. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
    Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW.
    J Clin Oncol; 1998 Oct 12; 16(10):3270-8. PubMed ID: 9779701
    [Abstract] [Full Text] [Related]

  • 14. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH, Geerlings MW, Warrell RP, Larson SM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG, Verschraegen CF, Murray JL, Kudelka AP, Gano J, Cheung L, Kavanagh JJ.
    Clin Cancer Res; 1999 May 01; 5(5):953-61. PubMed ID: 10353726
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
    Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):777-86. PubMed ID: 15701868
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T.
    Lancet; 1995 Aug 05; 346(8971):336-40. PubMed ID: 7623531
    [Abstract] [Full Text] [Related]

  • 19. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA, DeNardo GL, Yuan A, Shen S, DeNardo SJ, Macey DJ, Lamborn KR, Mahe M, Groch MW, Erwin WD.
    J Nucl Med; 1996 Dec 05; 37(12):1970-5. PubMed ID: 8970516
    [Abstract] [Full Text] [Related]

  • 20. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
    Matthews DC, Badger CC, Fisher DR, Hui TE, Nourigat C, Appelbaum FR, Martin PJ, Bernstein ID.
    Cancer Res; 1992 Mar 01; 52(5):1228-34. PubMed ID: 1531324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.